Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.
We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-gamma). Forty-four patients with metastatic cancer were given rIFN-gamma at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-gamma resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for anti-interferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regression consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-gamma are indicated.
D000380:Agranulocytosis / Q000139:chemically induced; D000906:Antibodies / Q000032:analysis; D001835:Body Weight; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000032:analysis
D000906:Antibodies; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D007371:Interferon-gamma